These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 25759263)

  • 21. L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum.
    Wang Y; Wang HS; Wang T; Huang C; Liu J
    J Neurosci Res; 2014 Dec; 92(12):1733-45. PubMed ID: 24975553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aberrant restoration of spines and their synapses in L-DOPA-induced dyskinesia: involvement of corticostriatal but not thalamostriatal synapses.
    Zhang Y; Meredith GE; Mendoza-Elias N; Rademacher DJ; Tseng KY; Steece-Collier K
    J Neurosci; 2013 Jul; 33(28):11655-67. PubMed ID: 23843533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of depotentiation at basal ganglia output neurons in PD patients with levodopa-induced dyskinesia.
    Prescott IA; Liu LD; Dostrovsky JO; Hodaie M; Lozano AM; Hutchison WD
    Neurobiol Dis; 2014 Nov; 71():24-33. PubMed ID: 25116960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss and remodeling of striatal dendritic spines in Parkinson's disease: from homeostasis to maladaptive plasticity?
    Villalba RM; Smith Y
    J Neural Transm (Vienna); 2018 Mar; 125(3):431-447. PubMed ID: 28540422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia.
    Bartlett MJ; Flores AJ; Ye T; Smidt SI; Dollish HK; Stancati JA; Farrell DC; Parent KL; Doyle KP; Besselsen DG; Heien ML; Cowen SL; Steece-Collier K; Sherman SJ; Falk T
    Exp Neurol; 2020 Nov; 333():113413. PubMed ID: 32717354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    Cenci MA
    Amino Acids; 2002; 23(1-3):105-9. PubMed ID: 12373525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia.
    Cenci MA; Lundblad M
    J Neurochem; 2006 Oct; 99(2):381-92. PubMed ID: 16942598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Striatal spine plasticity in Parkinson's disease: pathological or not?
    Smith Y; Villalba RM; Raju DV
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3(Suppl 3):S156-61. PubMed ID: 20082980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Striatal synaptic changes in experimental parkinsonism: role of NMDA receptor trafficking in PSD.
    Picconi B; Ghiglieri V; Bagetta V; Barone I; Sgobio C; Calabresi P
    Parkinsonism Relat Disord; 2008; 14 Suppl 2():S145-9. PubMed ID: 18583173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P; Tremblay L; Féger J; Hirsch EC
    Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Pavón N; Martín AB; Mendialdua A; Moratalla R
    Biol Psychiatry; 2006 Jan; 59(1):64-74. PubMed ID: 16139809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    Shin E; Rogers JT; Devoto P; Björklund A; Carta M
    Exp Neurol; 2014 Jul; 257():25-38. PubMed ID: 24747357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Striatal plasticity in Parkinson's disease and L-dopa induced dyskinesia.
    Iravani MM; McCreary AC; Jenner P
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S123-5. PubMed ID: 22166408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia.
    Fieblinger T; Graves SM; Sebel LE; Alcacer C; Plotkin JL; Gertler TS; Chan CS; Heiman M; Greengard P; Cenci MA; Surmeier DJ
    Nat Commun; 2014 Oct; 5():5316. PubMed ID: 25360704
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
    Tamim MK; Samadi P; Morissette M; Grégoire L; Ouattara B; Lévesque D; Rouillard C; Di Paolo T
    Neuropharmacology; 2010 Jan; 58(1):286-96. PubMed ID: 19576910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
    Darmopil S; Martín AB; De Diego IR; Ares S; Moratalla R
    Biol Psychiatry; 2009 Sep; 66(6):603-13. PubMed ID: 19520364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Striatal synaptic plasticity: implications for motor learning and Parkinson's disease.
    Pisani A; Centonze D; Bernardi G; Calabresi P
    Mov Disord; 2005 Apr; 20(4):395-402. PubMed ID: 15719415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia.
    Picconi B; Bagetta V; Ghiglieri V; Paillè V; Di Filippo M; Pendolino V; Tozzi A; Giampà C; Fusco FR; Sgobio C; Calabresi P
    Brain; 2011 Feb; 134(Pt 2):375-87. PubMed ID: 21183486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
    Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
    Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.